hematologic toxicity caused by accumulation of the active metabolite gemcitabine triphosphate. 22 
SUPPORTIVE CARE
A. Acute Emesis Prophylaxis: The CapGem regimen is predicted to cause acute emesis in 10% to 30% of patients. [23] [24] [25] [26] The studies reviewed reported nausea in 21% to 55% of patients, 6, 20 with grade 3 or 4 nausea in 2% to 7% of patients. 4, 6, 14, 20 Vomiting was reported in 34% of patients, 6 with grade 3 or 4 vomiting reported in 2% to 4% of patients. 4, 6, 14 Prophylactic antiemetic therapy with a serotonin antagonist is recommended, [24] [25] [26] but may not be required in all patients. One group suggests addition of a neurokinin (NK 1 ) antago-nist may be appropriate in some patients. 24 One of the following regimens given 30 minutes prior to therapy is recommended: 1. Ondansetron 8 mg to 16 mg orally (PO), ±dexamethasone 12 mg PO, given 30 minutes before CapGem. 2. Granisetron 1 mg to 2 mg PO, ±dexamethasone 12 mg PO, given 30 minutes before CapGem. 3. Dolasetron 100 mg PO, ±dexamethasone 12 mg PO, given 30 minutes before CapGem. 4. Palonosetron 0.25 mg IV and dexamethasone 12 mg PO, given 30 minutes before CapGem on day 1 only. Prophylactic use of a NK 1 antagonist is recommended for moderately emetogenic regimens Table 1 . GemCAP regimen [3] [4] [5] [6] 9, 12, 14, 15, 20 18 if the 2-drug combination was not effective in the previous treatment cycle. [24] [25] [26] One of the following regimens is recommended: 1. Ondansetron 8 mg to 16 The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid or steroid and dopamine antagonist combination most appropriate for follow-up therapy. 27 One of the following regimens is recommended: Patients who experience signifi cant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [23] [24] [25] [26] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [28] [29] [30] [31] [32] B. Breakthrough Nausea and Vomiting [23] [24] [25] [26] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: Patients who do experience signifi cant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [23] [24] [25] [26] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [28] [29] [30] [31] [32] C. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSF) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSF should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSF is not recommended. 33, 34 Since febrile neutropenia was reported in only 1% to 7% of patients in the studies reviewed, 3, 4, 14 prophylactic use of CSF is not recommended. 32, 33 CSF may be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of CapGem. D. Diarrhea: Diarrhea is a frequent consequence of capecitabine administration. Diarrhea is usually mild to moderate, responding to conventional therapy. Occasionally, the problem can be severe or dose-limiting. Patients should receive a prescription for an antidiarrheal agent for use at the onset of diarrhea. The standard recommendation is loperamide 4 mg PO at the onset of diarrhea, followed by 2 mg PO after each unformed stool, or as often as every 2 hours for 24 hours. 35 Patients should be counseled to 36 
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Ascites (grade 3) 8%, 9 dehydration (grade 3) 8%, 9 lower extremity deep venous thrombosis (grade 4) 8%, 9 pleural effusion (grade 3) 8%, 9 pulmonary embolism (grade 4) 8%, 9 thromboembolic events (grade 4) (grade 2) 2%. 3 (grade 2) 2%. 4 C. Constitutional: Fatigue 73%, 6 (grade 2) 42%, 3 (grade 3) 4% to 8%, 3, 9 (grade 3 or 4) 11% 6 ; fever (grade 2) 2% 3 ; weakness (grade 2) 3%. 4 D. Dermatologic: Hand-foot rash (grade 2) 20%, 3 (grade 3) 9% 3 ; skin rash 16%, 20 (grade 2) 2%. 3 E. Endocrine/metabolic: Hyperglycemia (grade 3) 17%, 9 hyperkalemia (grade 3) 8%. 9 F. Gastrointestinal: Anorexia 59%, 6 (grade 2) 3%, 4 (grade 3) 2%, 4 (grade 3 or 4) 7% 6 ; constipation (grade 2) 5%, 4 (grade 3) 2%, 4, 12 (grade 4) 8% 9 ; diarrhea 23%, 6 (grade 2) 2%, 3 (grade 3) 2% to 8%, 9, 12 (grade 3 or 4) 2% to 5% 6, 14 ; mucositis/ stomatitis 9%, 6 (grade 2) 9% 3 ; nausea 21% to 55%, 6, 20 (grade 2) 7% to 12%, 3, 4 (grade 3) 2%, 4 (grade 3 or 4) 5% to 7% 6, 14, 20 ; vomiting 34%, 6 (grade 2) 2% to 8%, 3, 4 (grade 3) 3%, 4 (grade 3 or 4) 2% to 4%. 6,14 G. Hematologic: Anemia 53% to 93%, 6, 20 (grade 3) 8% to 9%, 9, 12 (grade 3 or 4) 2% to 8% 6, 14, 20 ; epistaxis (grade 3) 8%, 9 febrile neutropenia (grade 3) 2% to 7%, 3, 4 (grade 3 or 4) 1% 14 ; gastrointestinal bleeding (grade 3) 1% 5 ; increased prothrombin time (grade 3) 8%; 9 leukopenia 82%, 6 (grade 3 or 4) 11% 6 ; neutropenia 74%, 20 (grade 2) 33%, 3 (grade 3) 1% to 32%, [3] [4] [5] 9, 12 (grade 3 or 4) 23% to 37%, 14, 20 (grade 4) 2% to 9% 3, 12 ; thrombocytopenia 32% to 70%, 6, 20 (grade 2) 9%, 3 a. Greater than or equal to 100,000 cells/ mcL. 3,5,6,9,14 b . Greater than or equal to 120,000 cells/ mcL. 12 
B. Central Nervous System: Insomnia

Hemoglobin:
a. Greater than or equal to 10 g/dL. 14 
Serum creatinine:
a. Less than or equal to 1.8 mg/dL. 3, 5 b. Less than or equal to 1.6 mg/dL. 9 c. Less than or equal to 1.2 mg/dL. 12 6. Creatinine clearance: a. Greater than or equal to 60 mL/min. 3, 5 b. Greater than or equal to 50 mL/min. 6 c. Greater than or equal to 30 mL/min. 14 
Serum bilirubin:
a. Less than or equal to 3 times the upper limit of normal (ULN) and stable for 2 weeks. 3 b. Less than or equal to 3 times the ULN. 4,5 c. Less than or equal to 4 times the ULN. 6 d. Less than or equal to 5 times the ULN. 14 e. Less than 3 mg/dL. 9,12 8. ALT: a. Less than or equal to 5 times the ULN and stable for 2 weeks. 3 b. Less than or equal to 5 times the ULN. [4] [5] [6] 14 c. Within normal limits. 12 9. AST: a. Within normal limits. 12 b. Less than or equal to 5 times the ULN. 14 In clinical practice, a pretreatment ANC of 1,000 cells/mcL and platelets of 75,000 cells/ mcL are usually considered acceptable.
